Key Points
- Alkermes EVP Craig Hopkinson sold 9,000 shares on June 1 at an average price of $41.67, totaling about $375,030. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he still held 77,389 shares afterward.
- ALKS shares were trading near their 52-week high, opening at $42.27 and up 0.2% on the day. The stock has a 1-year range of $25.17 to $42.83 and a market value of about $7.05 billion.
- Analysts remain cautiously positive on Alkermes, with a consensus rating of “Moderate Buy” and an average target price of $45.40. Recent moves included price target hikes from Baird and Wells Fargo, while institutional ownership remains high at 95.21%.
Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig Hopkinson sold 9,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $41.67, for a total value of $375,030.00. Following the completion of the transaction, the executive vice president directly owned 77,389 shares in the company, valued at $3,224,799.63. The trade was a 10.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Alkermes Trading Up 0.2%
NASDAQ:ALKS opened at $42.27 on Tuesday. The firm has a market capitalization of $7.05 billion, a price-to-earnings ratio of 46.97 and a beta of 0.38. The company has a current ratio of 2.27, a quick ratio of 1.70 and a debt-to-equity ratio of 0.85. The business's 50-day moving average price is $34.77 and its two-hundred day moving average price is $31.86. Alkermes plc has a 1-year low of $25.17 and a 1-year high of $42.83.
Alkermes (NASDAQ:ALKS - Get Free Report) last released its quarterly earnings results on Saturday, February 14th. The company reported $0.29 EPS for the quarter. The company had revenue of $384.55 million for the quarter. Alkermes had a return on equity of 9.26% and a net margin of 9.78%. On average, equities analysts expect that Alkermes plc will post -0.43 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on ALKS. Robert W. Baird raised their price target on Alkermes from $45.00 to $48.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 13th. Wells Fargo & Company raised their price target on Alkermes from $43.00 to $44.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 6th. Wall Street Zen lowered Alkermes from a "buy" rating to a "hold" rating in a research report on Saturday, February 28th. Bank of America raised their price target on Alkermes from $34.00 to $36.00 and gave the stock a "neutral" rating in a research report on Thursday, April 9th. Finally, Truist Financial upgraded Alkermes to a "strong-buy" rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Alkermes presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.40.
Get Our Latest Stock Analysis on Alkermes
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Assetmark Inc. grew its stake in Alkermes by 933.8% in the third quarter. Assetmark Inc. now owns 827 shares of the company's stock valued at $25,000 after purchasing an additional 747 shares in the last quarter. Cullen Frost Bankers Inc. bought a new position in Alkermes in the fourth quarter valued at approximately $28,000. Johnson Financial Group Inc. bought a new position in Alkermes in the third quarter valued at approximately $31,000. UMB Bank n.a. grew its stake in Alkermes by 57.6% in the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company's stock valued at $34,000 after purchasing an additional 446 shares in the last quarter. Finally, Salomon & Ludwin LLC grew its stake in Alkermes by 115.6% in the fourth quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company's stock valued at $35,000 after purchasing an additional 667 shares in the last quarter. 95.21% of the stock is currently owned by institutional investors.
Alkermes Company Profile
(
Get Free Report)
Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.
Alkermes' commercial franchise features several approved products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
